Has David Sinclair publicly confirmed taking NMN, metformin, and resveratrol?

Yes. Sinclair has confirmed his use of all three compounds in his book *Lifespan* (2019), on the Joe Rogan Experience, on the Lex Fridman Podcast, and across his social media accounts. He has discussed specific doses and timing publicly.

Is NMN FDA-approved for anti-aging?

No. NMN is sold as a dietary supplement in the United States and is not FDA-approved for any disease indication. The FDA's 2022 decision to investigate NMN's regulatory status (supplement vs. investigational drug) created market uncertainty, but NMN products remain widely available. No completed Phase III trial has tested NMN for aging-related endpoints.

Does metformin actually extend human lifespan?

This is unproven. Observational data from diabetic populations suggests a possible mortality benefit, but confounders are significant. The TAME trial, designed to answer this question in non-diabetic adults, has not yet reported results. Metformin remains FDA-approved only for type 2 diabetes.

What are the main risks of following Sinclair's protocol without medical supervision?

Metformin requires a prescription and can cause GI side effects, vitamin B12 deficiency with long-term use, and may blunt exercise benefits. NMN and resveratrol lack long-term human safety data. Supplement quality varies widely, and third-party purity testing is not universal. Blood work monitoring (liver enzymes, glucose, B12, renal function) is strongly recommended by the HealthRX Medical Team.

Is resveratrol worth taking based on current evidence?

The human evidence is modest. Small improvements in metabolic markers have been reported, but effect sizes are inconsistent, and bioavailability is poor without fat co-ingestion. At standard doses (250 to 500 mg/day), safety signals are minimal. Whether it provides meaningful longevity benefit in humans remains unestablished.

The Medical Takeaways from David Sinclair's Longevity Story

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Who Is David Sinclair?

David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. He has published over 200 peer-reviewed papers on aging biology, co-founded several longevity-focused companies (including Life Biosciences and Metro Biotech), and authored the bestselling book Lifespan: Why We Age and Why We Don't Have To. His public profile rests on decades of sirtuin and NAD+ research, work that began with yeast models in the early 2000s and expanded to mammalian aging pathways.

Sinclair has confirmed his personal supplement and medication regimen in multiple public forums. In Lifespan (2019), he listed NMN, resveratrol, and metformin among the compounds he takes daily. He reiterated these disclosures on Joe Rogan's podcast (episodes #1234 and #1670), in a widely viewed appearance on the Lex Fridman Podcast, and across his own social media accounts. This is not speculation: Sinclair has openly discussed doses, timing, and his rationale.

What makes his case unusual is that he is both the researcher generating the preclinical data and a self-experimenter acting on it. That dual role matters for patients evaluating the same compounds.

The Three Pillars of Sinclair's Public Protocol

NMN (Nicotinamide Mononucleotide)

Sinclair has publicly stated he takes 1 gram of NMN per day, typically in the morning. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy metabolism, DNA repair, and sirtuin activation. Sinclair's own lab published landmark work showing that NMN supplementation restored NAD+ levels and improved vascular function in aged mice (Das et al., Cell, 2018).

In humans, the evidence is earlier-stage. A 2022 randomized controlled trial found that 250 mg/day of NMN for 12 weeks improved muscle insulin sensitivity in prediabetic postmenopausal women (Yoshino et al., Science, 2021). Another trial showed that NMN supplementation increased blood NAD+ concentrations in healthy adults, but hard clinical endpoints (disease prevention, lifespan extension) have not been established in human trials (Yi et al., GeroScience, 2023).

The HealthRX Medical Team notes a critical gap here: Sinclair's 1 g/day dose exceeds what most published human trials have tested. Dose-response data in humans remains thin, and long-term safety profiles beyond 12 months are not yet available in the peer-reviewed literature.

Metformin (Off-Label Longevity Use)

Sinclair has confirmed taking metformin, the first-line type 2 diabetes drug, for its potential geroprotective effects. He has discussed this in public lectures and in Lifespan. Metformin activates AMP-activated protein kinase (AMPK), reduces hepatic glucose production, and appears to modulate multiple aging-related pathways including mTOR signaling and inflammatory markers.

The observational evidence is intriguing. A 2014 analysis of UK clinical records found that diabetic patients on metformin had slightly lower all-cause mortality than matched non-diabetic controls (Bannister et al., Diabetes, Obesity and Metabolism, 2014). This finding catalyzed the TAME (Targeting Aging with Metformin) trial, a large-scale randomized trial designed to test whether metformin delays age-related diseases in non-diabetic older adults. TAME has faced funding delays, and as of 2026, results are not yet published.

For non-diabetic patients, metformin is an off-label prescription. Common side effects include gastrointestinal distress (nausea, diarrhea, abdominal cramping) in up to 25% of users. One concern specific to longevity-seekers who exercise: a 2019 randomized trial found that metformin blunted improvements in aerobic capacity and muscle mitochondrial respiration during exercise training in older adults (Konopka et al., Aging Cell, 2019). Sinclair himself has publicly noted that he skips metformin on days he exercises intensely, a practical adjustment that reflects this data.

Resveratrol

Sinclair takes resveratrol mixed with yogurt each morning, a detail he has shared repeatedly in interviews and on social media. His early career research demonstrated that resveratrol activates SIRT1, extending lifespan in yeast and improving metabolic health in obese mice (Baur et al., Nature, 2006).

Human translation has been disappointing. A 2014 meta-analysis in Journal of Clinical Endocrinology & Metabolism found modest improvements in fasting glucose and insulin levels, but effect sizes were small and inconsistent across populations. Bioavailability is a known limitation: oral resveratrol undergoes rapid first-pass metabolism, and plasma levels achievable through supplementation are far below the concentrations used in cell and animal studies (Walle et al., Drug Metabolism and Disposition, 2004).

The HealthRX Medical Team points out that Sinclair's practice of mixing resveratrol with fat (yogurt) reflects published evidence that fat co-ingestion increases absorption by roughly 5-fold. This is a pharmacokinetic detail most consumers miss when taking resveratrol with water or in capsule form on an empty stomach.

What Non-Celebrity Patients Should Actually Consider

At a glance

NMN: Sinclair takes 1 g/day; most human trials tested 250 mg/day. Long-term safety data beyond 12 months is absent. NAD+ blood levels do increase, but no human trial has shown lifespan extension.
Metformin: Off-label use requires a prescription. GI side effects affect up to 1 in 4 users. May blunt exercise adaptations. The TAME trial has not yet reported results.
Resveratrol: Bioavailability is poor without fat co-ingestion. Human effect sizes are modest compared to animal data. No serious safety signals at standard doses (250 to 500 mg/day), but also no strong efficacy signal for longevity endpoints.
Cost: NMN at 1 g/day runs $60 to $150/month depending on brand and purity. Resveratrol is cheaper ($15 to $40/month). Metformin is inexpensive with a prescription ($4 to $15/month generic).
Monitoring: Sinclair has publicly mentioned tracking his blood biomarkers. Any patient considering these compounds should work with a physician to monitor liver enzymes, fasting glucose, lipids, and kidney function.

The Dose Gap Between Research and Practice

Sinclair's doses are self-selected, not derived from completed dose-finding trials in humans. This is a pattern the HealthRX Medical Team sees repeatedly in longevity medicine: a prominent figure adopts a dose based on animal pharmacokinetics and personal blood work, and consumers replicate it without the same monitoring infrastructure. The 1 g NMN dose, for example, extrapolates from mouse studies where body-weight-adjusted doses showed benefit. Whether that translates linearly to humans is unknown.

Discontinuation and the "What If I Stop" Question

Patients often ask whether stopping NMN or resveratrol causes a rebound decline. No published human data addresses this question directly. In mouse models, NAD+ levels decline back to baseline after NMN cessation, which suggests that any benefits are maintenance-dependent rather than permanent (Mills et al., Cell Metabolism, 2016). The HealthRX Medical Team advises patients to think of these compounds, if they choose to take them, as ongoing interventions, not one-time fixes. Discontinuation planning should be discussed with a prescribing physician, particularly for metformin, which can cause rebound hyperglycemia in insulin-resistant individuals.

The Conflict-of-Interest Layer

Sinclair has financial interests in companies developing NAD+ boosters and longevity therapeutics. He has been transparent about this: in Lifespan, in SEC filings, and in public interviews. This does not invalidate his research, but the HealthRX Medical Team believes patients should weigh self-experimentation claims from any scientist who also holds equity in companies commercializing the same molecules. The clinical data should drive decisions, not the personal anecdote of any single practitioner, regardless of credentials.

The HealthRX Medical Team's Clinical Bottom Line

Sinclair's public disclosures have done something genuinely useful: they put NAD+ biology, metformin repurposing, and sirtuin activation into mainstream conversation. The research trajectory is real. But the gap between "promising preclinical data" and "proven human longevity intervention" remains wide.

For patients considering elements of this protocol, the HealthRX Medical Team recommends starting with the interventions that have the strongest human evidence base (metformin for metabolic risk, with physician oversight) before adding compounds with thinner clinical support (NMN, resveratrol). Dose conservatively. Monitor blood work. And recognize that the most evidence-backed longevity interventions remain the unglamorous ones: regular exercise, adequate sleep, caloric moderation, and blood pressure control, all supported by decades of epidemiological data.

Frequently asked questions

›

References

Das A, et al. Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging. Cell. 2018. PubMed
Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PubMed
Yi L, et al. The efficacy and safety of NMN supplementation in healthy middle-aged adults. GeroScience. 2023. PubMed
Bannister CA, et al. Can people with type 2 diabetes live longer than those without? Diabetes, Obesity and Metabolism. 2014. PubMed
Barzilai N, et al. Metformin as a tool to target aging. Cell Metabolism. 2016. PubMed
Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019. PubMed
Baur JA, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006. PubMed
Walle T, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. 2004. PubMed
Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016. PubMed
Li Y, et al. Impact of healthy lifestyle factors on life expectancies in the US population. Circulation. 2018. PubMed